Regulation
Eleven Senators Asked The FDA To Schedule The Whole Kratom Leaf. Seven Months Later The Federal Notice Answers Their Objection In One Sentence And Does Not Do What They Asked.

On October 9 the Department of Health and Human Services recommended that the Drug Enforcement Administration use concentration or ratio based thresholds to decide which 7-hydroxymitragynine and mitragynine pseudoindoxyl products are temporarily controlled. The department described the approach as separating concentrated or chemically altered products from natural botanical kratom, and its Assistant Secretary for Health was reported as saying natural kratom would not be affected.
In coverage of that recommendation Senator Pete Ricketts of Nebraska called the step a good start and said the whole kratom leaf should be scheduled as well.
He has been saying that since March, and he has not been saying it alone.
The Letter
On March 18, 2026, Ricketts and Senator Richard Blumenthal of Connecticut sent a letter to Food and Drug Administration Commissioner Martin Makary urging the agency to recommend scheduling for the kratom leaf itself, not only for the concentrated compound. Ricketts' own office names nine other signatories: Senators Blackburn, Boozman, Britt, Budd, Crapo, Daines, Justice, Padilla and Shaheen. That makes eleven in all, eight Republicans and three Democrats. Secondary accounts name fewer signatories, and the count given here is his office's.
The senators' argument runs in two parts. The first, on the accounts available, is that scheduling 7-hydroxymitragynine is an important first step. The second is the objection to stopping there, and it is the sentence this article turns on. "Singling out 7-OH to schedule," the letter says, "would leave these addictive products on the shelf and tacitly declare them safe for consumption."
The word addictive is the senators' own and is not adopted here. What matters is the structure of the objection, because it has since been answered, and not by a senator.
The Sentence
The most recent federal action is the notice of intent of October 14, which sets out the threshold approach and states that an order may publish on or after November 13. The notice contains a passage addressed to exactly the inference the senators warned about. Readers, it says, "should not infer from this notice of intent that DEA views 7-hydroxymitragynine or mitragynine pseudoindoxyl below this threshold as safe for consumption."
That is the agency's position and not this publication's. But both documents reach for the same phrase. The senators warned in March that acting on the compound alone would tacitly declare the rest "safe for consumption." The agency wrote in October that readers should not infer it views the rest as "safe for consumption." One is a prediction about what the document would be taken to say. The other is the document declining to say it.
A notice can disclaim an inference. Whether a market, a retailer or a state legislature reads the document that way is a separate question, and it is not one the notice can settle on its own. The senators' objection was never that the agency would say the rest was safe. It was that the rest would be treated as safe. Nothing in the record reviewed for this article addresses that second claim.
The Week The Two Chambers Went Opposite Directions
The letter is dated March 18. On March 19, the following day, Representative Gus Bilirakis of Florida introduced House Bill 8000, the END 7-OH Act, with two cosponsors reported as Representatives Buchanan and Lee. The bill would place synthetic 7-hydroxymitragynine in Schedule I and, on the accounts available, expressly leaves out the compound where it occurs naturally in the kratom plant.
The two documents point in opposite directions within twenty four hours. The Senate letter asks the executive branch to reach the leaf. The House bill writes a carve out for the leaf into statute. The bill was referred to the Committees on Energy and Commerce and the Judiciary, and the Health Subcommittee held a legislative hearing on it on March 26. No vote has been scheduled.
Both positions are seven months old and both are still where they were. What moved in the interval moved through the agencies, toward the compound and the threshold every time.
The Home States
The eleven signatories come from states that have already answered the question they are putting to the Food and Drug Administration, and they have not answered it the same way.
Connecticut, Blumenthal's state, scheduled. Public Act 25-101 required the Commissioner of Consumer Protection to designate seven substances, 7-hydroxymitragynine among them, and the state's Legislative Regulation Review Committee approved the resulting regulations unanimously. All seven became Schedule I substances and enforcement began on March 25, 2026, one week after the letter was sent. Tennessee, Senator Blackburn's state, prohibited every form of the plant effective July 1, as this publication reported this week.
Nebraska, Ricketts' state, did the other thing. The Legislature gave final approval to Legislative Bill 230, the Kratom Consumer Protection Act, in May 2025. It bars sales to anyone under twenty one, requires age verification by online sellers, mandates warning labels, requires federal good manufacturing practice rules, and assigns enforcement to the Attorney General. It also preempts cities and counties from setting stricter rules. Two competing measures in the same session, a prohibition and a controlled substance designation, did not become law.
So the senator asking Washington to schedule the leaf represents the state whose legislature chose to regulate it and to stop its own cities from going further. That is not a contradiction and is not presented as one. The ledger is stated because the letter is often described as a bipartisan federal consensus without anyone noting what the signatories' own states have done.
What An Operator Should Take From It
Two things, neither of them predictions.
The standing congressional ask covers the plant and every federal action so far covers concentration. Those are different objects, and a reader following only the agency documents would not know the broader ask exists. It has not expired either. Its lead signatory repeated it this month, in the same terms he used in March.
But no mechanism currently in motion does what the letter asks. The threshold notice does not. House Bill 8000 explicitly does not. A letter to a commissioner is not a vehicle, it is a request, and seven months of agency output have gone the other way.
What Is Not Established
Whether the Drug Enforcement Administration had the letter in view when it wrote that passage is not established and is not claimed here. They are set beside each other because the language matches, not because a causal link was found.
The letter was not read in full here, and only the sentence quoted above was confirmed against it. Whether the Food and Drug Administration has responded is not established here. Whether any signatory has introduced Senate legislation to the same effect was not found, and absence of a finding is not a finding of absence. The exact date of Senator Ricketts' October statement is not fixed here, only that it appeared in coverage of the October 9 recommendation. Party affiliations are given as of the signing.
No temporary scheduling order covering 7-hydroxymitragynine has published. The notice of intent of October 14 remains the most recent federal action.
Sourcing
The Federal Register notices, the text of House Bill 8000, the Connecticut regulation and the Nebraska bill file were all unreachable from where this was written. What is reported above as reported rests on search result summaries of those primary sources, on Ricketts' own press release as summarised, and on news coverage of the October recommendation.
Two passages are quoted. Both were confirmed against the documents themselves by a person who had them open rather than retrieved here. The sentence from the letter was confirmed after this article was drafted, which is why it stands in quotation marks and the rest of the letter's content does not. The sentence from the October 14 notice was confirmed the same way and is reproduced from this publication's reporting of October 15.
Everything else attributed to the letter, including its date, its signatories and the description of 7-OH scheduling as a first step, rests on summaries rather than on the document. That is why only one sentence of the letter appears here in quotation marks.
The Connecticut enforcement date and the Tennessee prohibition are this publication's own prior reporting.
Sources
- Office of Senator Pete Ricketts — letter calls on FDA to address kratom scheduling loophole
- Letter to the FDA on kratom regulation, March 18, 2026 (PDF)
- Department of Health and Human Services — recommendation on thresholds for enhanced kratom products
- WATE — HHS issues new recommendations, including Senator Ricketts' response
- United States Government Publishing Office — House Bill 8000, END 7-OH Act, as introduced
- Connecticut Department of Consumer Protection — controlled substance schedule updates
- Nebraska Legislature — Legislative Bill 230, final version
- The Kratom Council — the October 14 notice of intent and what it says
- The Kratom Council — state prohibitions, including Connecticut since March 25
Get new reporting by email
Federal and state kratom policy, enforcement actions and court decisions — sent when we publish, and nothing else.
The Kratom Council does not sell kratom. This list is used only to send our own articles — never product marketing, and it is never shared with or merged into any retailer’s mailing list. Unsubscribe any time.
